Monica B. Arniella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Monica B. Arniella has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Chow
Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2 shared publications Arvind Ravi
Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, USA
2 shared publicationsChip Stewart
Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, USA
2 shared publications- Gad Getz
Broad Institute of MIT and Harvard, Cambridge, USA
2 shared publications Jaegil Kim
GlaxoSmithKline, Waltham, USA
2 shared publications- Jedd D. Wolchok
Weill Cornell Medicine 29 New York, NY
2 shared publications
Latest Publications
- Open Access
Error correction of SARS-CoV-2 genomic sequences using a phylogenetic prior
Genotype calling of sequencing data has improved over recent years thanks to technological and statistical breakthroughs. One such advance is the use of imputation-based genotyping methods in human genetics. For haploid and mostly non-recombining organisms, a natural equivalent is to leverage phylogenetic signal for imputation-based genotype calling. SARS-CoV-2 is one such case, and the use of improved genotyping methods in this species is particularly pertinent given the well-documented systematic problems with read alignment and assembly in rapidly evolving regions of its genome, motivating the need for statistically principled methods for genotype correction that complement existing community efforts to curate sequencing data. We present a statistical framework to combine phylogenetic prior probabilities with the information from aligned reads, and demonstrate its utility in correcting consensus calls made on short-read, viral sequencing data. We derive phylogenetically-informed posterior probabilities based on genome placement in a reference phylogeny, and read likelihoods calculated from machine-reported base quality scores. We further modify the prior at each site by estimating a maximum-likelihood scaling parameter jointly with reads at all other sites. We find that the phylogenetically-informed base calling method stays highly accurate across simulated depth and error conditions. In real datasets, the method vastly improves call rate while still maintaining similar accuracy as reference-based assembly methods. In problematic genomic regions, the phylogenetically-informed method confers both accuracy and call rate gains. Accuracy and call rate do not stratify with sequencing center and primer scheme used, suggesting broad applicability across sequencing technologies and potentially diverging sequences. Our results in real and simulated data demonstrate that phylogenetically-informed genotyping correction results in more complete sequences, achieving a higher call rate without compromising accuracy. In cases of low mean depth, sparse coverage, or difficult-to-sequence regions that may still retain a low call rate, the method improves the accuracy of genotype calls.
Open AccessError correction of SARS-CoV-2 genomic sequences using a phylogenetic prior
Genotype calling of sequencing data has improved over recent years thanks to technological and statistical breakthroughs. One such advance is the use of imputation-based genotyping methods in human genetics. For haploid and mostly non-recombining organisms, a natural equivalent is to leverage phylogenetic signal for imputation-based genotype calling. SARS-CoV-2 is one such case, and the use of improved genotyping methods in this species is particularly pertinent given the well-documented systematic problems with read alignment and assembly in rapidly evolving regions of its genome, motivating the need for statistically principled methods for genotype correction that complement existing community efforts to curate sequencing data. We present a statistical framework to combine phylogenetic prior probabilities with the information from aligned reads, and demonstrate its utility in correcting consensus calls made on short-read, viral sequencing data. We derive phylogenetically-informed posterior probabilities based on genome placement in a reference phylogeny, and read likelihoods calculated from machine-reported base quality scores. We further modify the prior at each site by estimating a maximum-likelihood scaling parameter jointly with reads at all other sites. We find that the phylogenetically-informed base calling method stays highly accurate across simulated depth and error conditions. In real datasets, the method vastly improves call rate while still maintaining similar accuracy as reference-based assembly methods. In problematic genomic regions, the phylogenetically-informed method confers both accuracy and call rate gains. Accuracy and call rate do not stratify with sequencing center and primer scheme used, suggesting broad applicability across sequencing technologies and potentially diverging sequences. Our results in real and simulated data demonstrate that phylogenetically-informed genotyping correction results in more complete sequences, achieving a higher call rate without compromising accuracy. In cases of low mean depth, sparse coverage, or difficult-to-sequence regions that may still retain a low call rate, the method improves the accuracy of genotype calls.
- Top Cited PapersOpen Access
- 6 April 2023
- Published by Springer Nature in Nature Genetics
- Vol. 55 (5) , 807-819
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with NSCLC treated with anti-PD-(L)1 therapy, along with matched clinical response annotation. We identify a number of associations between molecular features and outcome, including (1) favorable (for example, ATM altered) and unfavorable (for example, TERT amplified) genomic subgroups, (2) a prominent association between expression of inducible components of the immunoproteasome and response and (3) a dedifferentiated tumor-intrinsic subtype with enhanced response to checkpoint blockade. Taken together, results from this cohort demonstrate the complexity of biological determinants underlying immunotherapy outcomes and reinforce the discovery potential of integrative analysis within large, well-curated, cancer-specific cohorts.
- 6 April 2023
- Published by Springer Nature in Nature Genetics
- Vol. 55 (5) , 807-819
Top Cited PapersOpen AccessGenomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with NSCLC treated with anti-PD-(L)1 therapy, along with matched clinical response annotation. We identify a number of associations between molecular features and outcome, including (1) favorable (for example, ATM altered) and unfavorable (for example, TERT amplified) genomic subgroups, (2) a prominent association between expression of inducible components of the immunoproteasome and response and (3) a dedifferentiated tumor-intrinsic subtype with enhanced response to checkpoint blockade. Taken together, results from this cohort demonstrate the complexity of biological determinants underlying immunotherapy outcomes and reinforce the discovery potential of integrative analysis within large, well-curated, cancer-specific cohorts.
- Open Access
- 23 May 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (6)
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions
Transcription factors ThPOK and Runx3 regulate the differentiation of “helper” CD4+ and “cytotoxic” CD8+ T cell lineages respectively, inducing single positive (SP) T cells that enter the periphery with the expression of either the CD4 or CD8 co-receptor. Despite the expectation that these cell fates are mutually exclusive and that mature CD4+CD8+ double positive (DP) T cells are present in healthy individuals and augmented in the context of disease, yet their molecular features and pathophysiologic role are disputed. Here, we show DP T cells in murine and human tumors as a heterogenous population originating from SP T cells which re-express the opposite co-receptor and acquire features of the opposite cell type’s phenotype and function following TCR stimulation. We identified distinct clonally expanded DP T cells in human melanoma and lung cancer by scRNA sequencing and demonstrated their tumor reactivity in cytotoxicity assays. Our findings indicate that antigen stimulation induces SP T cells to differentiate into DP T cell subsets gaining in polyfunctional characteristics.
- 23 May 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (6)
Open AccessTumor-induced double positive T cells display distinct lineage commitment mechanisms and functions
Transcription factors ThPOK and Runx3 regulate the differentiation of “helper” CD4+ and “cytotoxic” CD8+ T cell lineages respectively, inducing single positive (SP) T cells that enter the periphery with the expression of either the CD4 or CD8 co-receptor. Despite the expectation that these cell fates are mutually exclusive and that mature CD4+CD8+ double positive (DP) T cells are present in healthy individuals and augmented in the context of disease, yet their molecular features and pathophysiologic role are disputed. Here, we show DP T cells in murine and human tumors as a heterogenous population originating from SP T cells which re-express the opposite co-receptor and acquire features of the opposite cell type’s phenotype and function following TCR stimulation. We identified distinct clonally expanded DP T cells in human melanoma and lung cancer by scRNA sequencing and demonstrated their tumor reactivity in cytotoxicity assays. Our findings indicate that antigen stimulation induces SP T cells to differentiate into DP T cell subsets gaining in polyfunctional characteristics.
- Open Access
- 15 February 2022
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (2) , 100500
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma
- 15 February 2022
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (2) , 100500
Open AccessCombined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma